CervoMed Inc. (CRVO) Stock Score, Valuation & Financial Research

CervoMed Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CRVO

CervoMed Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.34. These figures are a research snapshot, not a buy or sell recommendation.

What CervoMed Inc. does

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

CervoMed is a clinical-stage biotechnology company that does not currently generate commercial revenue from product sales. Its business model relies on funding research and development through equity financings, grants, and potential future out-licensing or commercialization of its lead product candidate, neflamapimod, for age-related neurologic disorders.

Products and services

  • The company's primary product candidate is neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase, currently in clinical development for the treatment of dementia with Lewy bodies (DLB) and other neurodegenerative conditions.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and manage development activities. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturers for the production of its clinical trial drug supplies. Source

Business strengths to evaluate

  • Clinical development progress of neflamapimod Source
  • Intellectual property portfolio in major international markets Source

Business risks and research considerations

  • History of operating losses and lack of commercial revenue Source
  • Dependence on clinical trial success and regulatory approval Source
  • Need for additional capital to fund future operations Source

Sources: Company research source · Intellectual property portfolio in major international markets

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CRVO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.34
Market capitalization:
30.92M (currency not supplied)
Revenue:
USD 322.57K
Net income:
USD -30.35M
Free cash flow:
USD -23.45M
Cash:
USD 22.46M
Total debt:
USD 0.00
EPS:
USD -3.21

What stands out

  • Free cash flow is USD -23.45M, negative for the stored period.
  • The balance sheet shows USD 22.46M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -7269.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -9408.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 22.46M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CRVO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CRVO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CRVO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CRVO to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of CRVO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research CRVO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.